View Older Stories View More Recent Stories

Dec 12, 2019 06:45AM Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KR
Dec 9, 2019 06:46AM Merck (MRK) to Acquire ArQule (ARQL) for $20/Share in $2.7B Deal
Dec 9, 2019 06:45AM Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 5, 2019 06:49AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Approved in China as First-Line Maintenance Therapy in BRCAm Advanced Ovarian Cancer
Dec 5, 2019 06:45AM LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
Dec 2, 2019 06:55AM Merck to Present at the Evercore ISI HealthCONx Conference 2019
Dec 2, 2019 06:46AM Merck (MRK) Announces FDA Grants Priority Review to its sBLA for KEYTRUDA in Certain Patients with High-Risk, NMIBC
Dec 2, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Nov 26, 2019 08:00AM Japan and Singapore Grant CRISPR Patents to MilliporeSigma
Nov 26, 2019 06:48AM Merck's (MRK) KEYTRUDA Now Approved in China for First-Line Treatment of Metastatic Squamous NSCLC in Combination with Chemotherapy
Nov 26, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Nov 25, 2019 06:45AM New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors
Nov 20, 2019 06:48AM Merck (MRK) Reports EC Approval for Two New Regimens of KEYTRUDA (pembrolizumab) as 1st-Line Treatment for Metastatic or Unresectable Recurrent HNSCC
Nov 20, 2019 06:45AM European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Nov 19, 2019 12:43PM Merck Announces First-Quarter 2020 Dividend
Nov 18, 2019 06:31AM Merck (MRK), Bayer’s Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 18, 2019 06:30AM Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 15, 2019 06:46AM Merck's (MRK) BRAVECTO PLUS for Cats Receives Approval from US FDA
Nov 15, 2019 06:45AM BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration
Nov 14, 2019 06:55AM US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review
Nov 12, 2019 08:00AM MilliporeSigma Licenses CRISPR Gene-Editing Technology to Evotec
Nov 11, 2019 03:02PM Merck's (MRK) ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in European Union
Nov 11, 2019 03:00PM Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Nov 8, 2019 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 29, 2019 06:45AM Merck Announces Third-Quarter 2019 Financial Results
Oct 28, 2019 02:00PM European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 18, 2019 07:02AM Merck (MRK) Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA as First-Line Treatment for Metastatic or Unresectable Recurrent HNSCC
Oct 18, 2019 07:00AM Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Oct 18, 2019 06:45AM Merck (MRK) Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine
Oct 18, 2019 06:45AM Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
Oct 10, 2019 07:30AM NexTech Appoints New Chief Financial Officer
Oct 8, 2019 08:00AM Merck Issues 2018/2019 Corporate Responsibility Report
Oct 2, 2019 10:44AM Agilent Technologies (A) Granted Approval for First PD-L1 Companion Diagnostic in China
Oct 2, 2019 06:48AM Merck's (MRK) KEYTRUDA Now Approved in China for First-Line Treatment of Certain Patients with Advanced NSCLC Whose Tumors Express PD-L1
Oct 2, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Oct 2, 2019 06:31AM Merck (MRK) Announces FDA Accepts Two Applications for its DIFICID to Treat Children with Clostridium difficile Infections
Oct 2, 2019 06:30AM FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
Oct 1, 2019 06:55AM Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29
Sep 30, 2019 10:32AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA More Than Doubled Median rPFS in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care
Sep 30, 2019 10:30AM LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)
Sep 30, 2019 06:55AM Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 30, 2019 06:49AM Merck (MRK) Announces Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO in HABP/VABP Met Primary Endpoint
Sep 30, 2019 06:45AM Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint
Sep 30, 2019 06:37AM Merck's (MRK) KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage TNBC
Sep 29, 2019 10:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Nega
Sep 29, 2019 02:30AM Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Sep 28, 2019 10:30AM LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer
Sep 27, 2019 02:00AM New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 20, 2019 08:11AM Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC
Sep 20, 2019 08:10AM CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
View More Recent Stories View Older Stories